A man who cannot move his arms picks up his phone and opens a messaging app. No voice, no hands — just a thought. The chip that made it possible never touched his brain tissue.
That is the bet behind Synchron, a New York–based neurotech company that has become the quiet counterweight to the louder names in the brain-computer interface (脑机接口) race. Where most implants require drilling into the skull, Synchron slides its device in through a blood vessel.
A stent, not brain surgery
Synchron's product is called the Stentrode. It is, in essence, a stent — the same kind of mesh tube used to hold open a blocked artery — studded with electrodes. A neurointerventionalist threads it up the jugular vein and parks it inside the superior sagittal sinus, a large vein that runs directly over the brain's motor cortex. Once in place, the mesh expands against the vessel wall and records neural signals passing through, without ever penetrating brain tissue.
The procedure looks far more like placing a cardiac stent than like brain surgery. There is no craniotomy, no surgical robot, and no lengthy neurosurgical opening. For patients with severe paralysis — the company's early focus — that difference is the whole point. The people who need a brain-computer interface (脑机接口) most are often the least able to survive an invasive operation.
What the trials actually show
Synchron is not a slide-deck company. Its COMMAND trial (NCT05035823) enrolled six patients with severe paralysis in the United States and Australia and followed them for up to twelve months. The results, published in JAMA Neurology in 2024, found that participants could control a computer using the implant, with no serious device-related adverse events over the study period. An earlier SWITCH study (NCT03834857) looked at ALS patients and similarly reported a clean safety picture.
Those two studies are why Synchron holds a distinctive regulatory position. The U.S. Food and Drug Administration granted the Stentrode a "Breakthrough Device" designation in 2020, and in 2021 Synchron became the first company to receive an FDA Investigational Device Exemption for a permanently implantable brain-computer interface (脑机接口) — a full year before its better-known competitors entered human trials.
The company says it has now implanted the device in roughly a dozen people across its U.S. and Australian programs. Patients have used it to send texts, write emails, and control tablets.
From the lab to the living room
What has pushed Synchron into the spotlight in 2024 and 2025 is not a new electrode but a string of partnerships that turn a research implant into a consumer-facing tool.
- In July 2024, Synchron demonstrated a patient controlling Apple's Vision Pro headset with thought alone.
- In January 2025, it announced a collaboration with NVIDIA to run real-time neural processing on the Holoscan platform and to build what it calls a "cognitive AI" foundation model trained on de-identified neural data.
- In May 2025, Synchron and Apple introduced a Brain-Computer Interface Human Interface Device (BCI HID) protocol, letting neural signals act as a native input for iPhone, iPad, and Vision Pro — meaning a paralyzed person's thoughts are formally recognized by mainstream operating systems as a form of "touch."
- Earlier integrations connected the implant to Amazon's Alexa (2024) and to OpenAI's models for hands-free chat.
For a field where most demonstrations still happen inside a research lab, Synchron's move into shipping consumer platforms is unusual.
The trade-off nobody mentions
The endovascular approach has a clear ceiling. Because the Stentrode reads through a vein wall rather than from inside the cortex, its signal is lower-resolution than that of penetrating arrays that sit among individual neurons. Synchron is not promising a paralyzed person will soon type at the speed of natural speech. It is promising something arguably more valuable for a first product: a safe, familiar, stent-like procedure that a standard interventional team can perform.
That is a different commercial logic. If the bandwidth is "good enough" for cursor control, texting, smart-home control, and basic computer use, the addressable population expands from a handful of trial sites to any hospital that already runs catheter labs.
Why China watchers should care
Synchron is the global reference point for the interventional branch of the brain-computer interface (脑机接口) field, and Chinese teams are moving the same direction. Researchers at Nankai University and companies such as Sinoway (心玮医疗) have pursued vein-based implants as a "minimally invasive" alternative to open-brain devices, betting that safety and scalability will win the long game. The technical path differs in detail, but the strategic thesis — skip the skull, win the market — is shared.
Honest limitations
Figures on patient counts and partnership scope come from Synchron's own disclosures and company-backed press materials; independent long-term audits are not yet public. The Stentrode is still an investigational device in the United States, not a commercially approved product, and its communication bandwidth is materially lower than penetrating implants. The "cognitive AI" foundation model is an announced direction, not a shipped system. Comparative safety claims rest on small, company-run studies rather than head-to-head trials against other architectures.
What readers can do now
- If you or a family member lives with paralysis or ALS, ask treating neurologists whether a brain-computer interface (脑机接口) trial is recruiting nearby; Synchron and several competitors maintain public waitlists.
- Watch the regulatory path, not the demo videos. FDA Breakthrough and IDE status signal scrutiny, not approval — the real milestone is a cleared, reimbursable product.
- For builders and clinicians in China, the interventional route is where domestic hardware can realistically compete on safety and scale; track vein-based implants as a credible near-term branch of the field.